Impax Laboratories (IPXL) Initiates Challenges to Abbott's Patents in Connection to TRICOR
More News related to ABT
- Abbott (ABT) sues Teva (TEVA) over its drug for kidney patients, Zemplar
- The Deal Names Abbott Top Dealmaker for Second Consecutive Year
- Hilliard Lyons Downgrades Abbott Labs (ABT) to Long-Term Buy
- Abbott to Develop New Heart Failure Test on ARCHITECT(R) Immunochemistry Diagnostics Platform
- Morgan Joseph Initiates Coverage on Boston Scientific (BSX) with a Hold; Shares Fully Valued
More News related to IPXL
- Impax Laboratories Drives Stronger Performance with IBM Business Analytics
- Impax Laboratories to Present at the Credit Suisse 18th Annual Healthcare Conference
- Impax Laboratories Continues Trend of Solid Growth in Revenue, Profit and Earnings for the Third Quarter 2009
- Trading Radar for 11/03: UBS (UBS), Yamana Gold (AUY), Archer-Daniels (ADM), Royal Caribbean (RCL), Marathon (MRO) Report
- Impax Laboratories (IPXL) Initiates Challenges to Abbott's Patents in Connection to TRICOR
Impax Laboratories, Inc. (NASDAQ: IPXL) has initiated a challenge of the patents listed by Abbott Laboratories (NYSE: ABT) in connection with its TRICOR (fenofibrate) tablets, 48 mg and 145 mg.
Impax filed its Abbreviated New Drug Application ("ANDA") containing a Paragraph IV certification for a generic version of TRICOR(R) with the U.S. Food & Drug Administration ("FDA"). Following receipt of the notice from the FDA that Impax's ANDA had been accepted for filing, Impax notified the New Drug Application holder and patent owners of its Paragraph IV certification.
On October 29, 2009, Abbott Laboratories and Laboratoires Fournier S.A. filed suit for patent infringement against Impax in the United States District Court for the District of New Jersey. This action formally initiates the patent challenge process under the Hatch-Waxman Act.
Once the ANDA is approved by FDA, Global Pharmaceuticals, Impax's generic division, will commercialize the products.
According to Wolters Kluwer Health, aggregate U.S. sales of TRICOR were approximately $1.5 billion for the twelve-month period ending August 2009. [SM]
Related Categories
Corporate NewsStocks Mentioned
+0.68
-0.07Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
